Sun pharmaceutical industries consolidated quarterly results. Annexure to boards report 2019 annexure to boards report 2018 annexure to boards report 2017 annexure to boards report 2016 earnings call transcript q3 fy 20 webcast audio 38th annual j. Sun pharma annual report analysis business standard. Sun pharma laboratories limited financial reports, balance. Sun pharma s stake in taro will go up to more than 69 per cent from 66 per cent should the buyback be fully subscribed. The company has eight directors gautam bhailal doshi, sailesh trambaklal desai, and others. Over the last 20 years he has played a key role in senior leadership positions, principally in ranbaxy, cairn india, lupin and indal, dealing with unique business criticalities which led to the organisations realising their potential values. Annual report 200910 promotions like pg cme meets and symposia. Download the annual financial reports, corporate information at lupin limited here. Established in 1983, sun pharma is the largest indian pharmaceutical company both in terms of market capitalisation and turnover fy15. Annual report of overseas subsidiary companies 202014. However, the us and indian formulations are by far the core strengths. Analyze up to 10 years of full 10k annual reports and quarterly 10q sec filings for sun biopharma, inc.
Sun pharmaceutical industries balance sheets, financial. In compliance with clause 49 of the listing agreement with stock exchanges, the. Sun pharmaceutical industries detailed director reports covering sun pharma financial results and performance report. Sun pharma consolidated december 2019 net sales at rs 8,154. Annual report 2010 11 3 when the sector began serious investments in drug discovery in the country in the early 1990s, we began with certain advantages both in terms of infrastructure and people that helped the industry take off earlier than it otherwise would have. Download financial results, earnings call, presentations and more. Sun pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. Reviewing financial statements and draft audit report,including quarterly halfyearly financial information. Mar 26, 2020 sun pharmaceutical industries limited, also popularly known as sun pharma, is a listed public company. Meanwhile, management commentary suggests no mediumterm respite from. Annual reports for 20182019 minutes of the 83rd annual general meeting extract of annual return scrutinizers report on remote e. Biocon annual report oncotherapeutics biocon oncotherapeutics launched in 2006, biocon oncotherapeutics is committed to delivering novel yet affordable cancer therapies. Sun pharmaceutical industries balance sheets get the latest financial reports, balance sheets of sun pharmaceutical industries on the economic times.
Sun pharma offers a program for individuals who want to disclose violations of us fda requirements related to facilities or products owned or operated by ranbaxy prior to sun pharma s acquisition of ranbaxy. Download annual financial reports, coporate information. Reviewing with the management the annual financialstatements before submission to the board, focusingprimarily on. Sun pharma inds reports, company history, directors report. Our fi nancial performance was strong, we completed a signifi cant acquisition, enriched the portfolio of.
Financial year 2011 could be termed as eventful that has laid base for value. Sun pharmaceuticals sunp fy17 annual report emphasizes the companys efforts on building its specialty pipeline. Management discussion and analysis annual report 2010 11 9 globally, the indian pharmaceutical industry ranks 10th in terms of value and third in terms of volume source. The company manufactures and markets a large basket of pharmaceutical formulations in india, the us and several other markets across the world. Financial results download financial reports kansai. The balance sheet page of sun pharmaceutical industries ltd. The directors have pleasure in presentng the 53rd annual report and audited. Download annual report in pdf format 2019 2018 2017 2016 2015. Sun pharma inds reports, company history, directors. Jan 14, 2020 sun pharma laboratories limited is an unlisted public company. Key message from md 9 key message from md dear shareholders, i am elated to share that bafna pharma has achieved more feats in last fiscal. A copy of the annual report is also available on the website of the company.
The founding family continues to hold a majority stake in the company. The said integraton has been completed with efect from october 1, 20. At sun pharma, we are committed to ensure that every product we manufacture and distribute meets with and conforms over its shelf life to internationally accepted standards of quality, purity, e. Year 201617 together with the report of the auditors and the board thereon, as disclosed in the enclosed annual report. Financial results download financial reports kansai nerolac. Lanxess investors recent annual reports and quarterly reports. Download annual report in pdf format 2018 2017 2016 2015 2014 20 2011. Sun pharmaceutical industries profit and loss reports the. Today sun pharma is the second largest and the most profitable pharmaceutical company in india, as well as the largest pharmaceutical company by market capitalisation on the indian. The formed entity wa s the worlds fifth largest specialty.
The impregnable walls around top defensive stocks such as itc and sun pharma have cracked, as they have lost nearly 10% from their october peaks against nse nfitys fall of just a little over 1%. Rbl bank, best bank, investor relations, financial results. Annexure to corporate governancefor the year ended march 31, 2010. Sun pharma advanced research company brokerage reports. If you wish to learn more about the program, please click continue. Annual report chairmans message at its core, our strategic blueprint for the next decade diversifies risk and envisages the systematic unlocking of highgrowth and profitable new revenue streams across the pharmaceutical value chain with a view to delivering on goals in a riskier and more uncertain world. The annual report of sun p harma for fy 2014 highlight ed the significant points about the deal, and the opportunities as under. History 1983 sun pharma established with five psychiatry products and two person marketing team at vapi, gujarat. System and procedures are in place to ensure that each batch of the product manufactured by sun pharma is of right quality. Snbp sec filing 10k annual report for the fiscal year ending tuesday, december 31, 2019. The company started preparing consolidated financial statements from financial year. Strong chemistry departments at the iits, institutions such. Page 1 by continuing to use this site you consent to the use of cookies on your device as described in our cookie policy unless you have disabled them.
Rbl bank investor relations for stockholders, potential investors, financial analysts. Take a look at mrfs financial results over the years. Alembic pharmaceuticals limited annual report 2012 alembic pharmaceuticals limited annual report 201112 alembic pharmaceuticals limited annual report 2010 11. Sun pharmaceutical industries directors report, sun pharma. It was incorporated on 17 january, 1997 and is located in mumbai city, maharashtra. It was incorporated on 01 march, 1993 and is located in vadodara, gujarat. While acute care still dominates the market with over. The company has five directors naresh chand singhal, sailesh trambaklal desai, and others. Our annual report provides a wide range of information about our global business and how we are working, both within. Its comprehensive range of cancerchemotherapy and supportive drugs are led by biomab egfr a humanized monoclonal antibody for head and neck cancer, abraxane a us fda. Annual report 2010 11 final resize sun pharma dd 1 82011 8. Sun pharma advanced research company brokerage report, sun pharma advanced research company updates and more at business standard news.
1166 1256 1318 1320 540 1326 542 1299 303 1329 1441 167 944 1571 1581 842 987 23 596 613 112 310 1255 1146 60 623 735 661 524 269 825 675 401